A novel hybrid peptide targeting EGFR-expressing cancers

European Journal of Cancer

Volumn 47, Issue 5, 2011, Pages 773-783

  Kohno, Masayuki ^a   Horibe, Tomohisa ^a   Haramoto, Mari ^a   Yano, Yoshiaki ^a   Ohara, Koji ^a   Nakajima, Oumi ^a   Matsuzaki, Katsumi ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Drug resistance; Drug targeting; EGFR; Hybrid peptide; Immunotoxins

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CANCER MODEL; CELL DESTRUCTION; CELL KILLING; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MUTANT CHIMERIC PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 79952106661     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.10.021     Document Type: Article

References (33)

1. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
2. I. Pastan Targeted therapy of cancer with recombinant immunotoxins Biochim Biophys Acta 1333 1997 C1 C6
3. K. Kawakami, O. Nakajima, R. Morishita, and R. Nagai Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties The Sci World J 6 2006 781 790
4. R.J. Kreitman Immunotoxins for targeted cancer therapy AAPS J 8 2006 E532 E551
5. R.W. Rand, R.J. Kreitman, and N. Patronas Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma Clin Cancer Res 6 2000 2157 2165 (Pubitemid 30399180)
6. S. Kunwar, M.D. Prados, and S.M. Chang Cintredekin Besudotox Intraparenchymal Study Group.Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group J Clin Oncol 25 2007 837 844 (Pubitemid 350002884)
7. A.E. Frankel, R.J. Kreitman, and E.A. Sausville Targeted toxins Clin Cancer Res 6 2000 326 334 (Pubitemid 30111447)
8. V. Grunwald, and M. Hidalgo Developing inhibitors of the epidermal growth factor receptor for cancer treatment J Natl Cancer Inst 95 2003 851 867 (Pubitemid 36833877)
9. P.A. Janne, J.A. Engelman, and B.E. Johnson Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 2005 3227 3234 (Pubitemid 46211347)
10. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 1999 241 250 (Pubitemid 29255919)
11. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
12. Z. Li, R. Zhao, and X. Wu Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics FASEB J 19 2005 1978 1985 (Pubitemid 41759743)
13. G. Yao, W. Chen, and H. Luo Identification of core functional region of murine IL-4 using peptide phage display and molecular modeling Int Immunol 18 2005 19 29 (Pubitemid 43057033)
14. S. Lien, and H.B. Lowman Therapeutic peptides Trends Biotechnol 21 2003 556 562 (Pubitemid 37415008)
15. S. Fuessel, A. Meye, and M. Schmitz Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial Prostate 66 2006 811 821
16. M. Chromek, Z. Slamová, and P. Bergman The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection Nat Med 12 2006 636 641 (Pubitemid 43865231)
17. R.P. Kuma, H. Wu, and J.L. McBride Transvascular delivery of small interfering RNA to the central nervous system Nature 448 2007 39 43 (Pubitemid 47037001)
18. H.M. Ellerby, W. Arap, and L.M. Ellerby Anti-cancer activity of targeted pro-apoptotic peptides Nat Med 5 1999 1032 1038 (Pubitemid 29439574)
19. J. Plescia, W. Salz, and F. Xia Rational design of shepherdin, a novel anticancer agent Cancer Cell 7 2005 457 468 (Pubitemid 40719129)
20. N. Papo, and Y. Shai New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells Biochemistry 42 2003 9346 9354 (Pubitemid 36959242)
21. N. Papo, A. Braunstein, Z. Eshhar, and Y. Shai Suppression of human prostate tumor growth in mice by a cytolytic D-L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion Cancer Res 64 2004 5779 5786 (Pubitemid 39095578)
22. Y. Imura, N. Choda, and K. Matsuzaki Magainin 2 in action: distinct modes of membrane permeabilization in living bacterial and mammalian cells Biophys J 95 2008 5757 5765
23. M. Mathew, and R.S. Verma Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy Cancer Sci 100 2009 1359 1365
24. A. Gschwind, O.M. Fischer, and A. Ullrich The discovery of receptor tyrosine kinases: targets for cancer therapy Nat Rev Cancer 4 2004 361 370 (Pubitemid 38579482)
25. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354 (Pubitemid 40637826)
26. M. Kawakami, K. Kawakami, and R.K. Puri Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells Cancer Immunol Immunother 50 2002 691 700 (Pubitemid 34146574)
27. N. Papo, D. Seger, and A. Makovitzki Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide Cancer Res 66 2006 5371 5378 (Pubitemid 43844963)
28. Y. Reiter, and I. Pastan Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis Trens Biotechnol 16 1998 513 520 (Pubitemid 28552663)
29. Z. Li, T. Yu, P. Zhao, and J. Ma Immunotoxins and cancer therapy Cell Mol Immunol 2 2005 106 112
30. J.A. Posey, M.B. Khazaeli, and M.A. Bookman A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors Clin Cancer Res 8 2002 3092 3099 (Pubitemid 35155018)
31. S. Kim, S.S. Kim, Y.J. Bang, S.J. Kim, and B.J. Lee In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines Peptides 24 2003 945 953 (Pubitemid 37130165)
32. A.J. Zurita, P. Troncoso, and M. Cardó-Vila Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer Cancer Res 64 2004 435 439 (Pubitemid 38120878)
33. K. Rege, S.J. Patel, Z. Megeed, and M.L. Yarmush Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells Cancer Res 67 2007 6368 6375 (Pubitemid 47037520)